Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cirkalm
- Development stage
- Phase 4
- Lead developer
- Pierre Fabre
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
**Cirkalm** is a topical fixed-dose medicinal cream developed and manufactured by Pierre Fabre for local treatment of anal pain. It combines *Ruscus aculeatus* extract, hesperidin methylchalcone, and sodium heparin. The formulation is intended to provide local venotonic, capillary-protective, anti-inflammatory, and anticoagulant effects in anorectal conditions. Pierre Fabre conducted a completed randomized, placebo-controlled Phase IV trial of Cirkalm cream for anal pain between October 2008 and December 2009 under protocol V00132 CR 401 and EudraCT number 2007-006029-29. ([clinicaltrials.pierre-fabre.com](https://clinicaltrials.pierre-fabre.com/en/study-v00132-cr-401/overview))
- Brand names
- Cirkalm
02
Targets
ATIII (Antithrombin III)
Beyond the preview
Go deeper on Cirkalm.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cirkalm.